Familial Mediterranean Fever, Non-Alcoholic Fatty Liver Disease
Conditions
Brief summary
Familial Mediterranean fever (FMF) affect liver and causes some dysfunctions including non-alcoholic fatty liver.. still exercise and diet limitation is the treatment for this case
Detailed description
Familial Mediterranean fever (FMF women with fatty liver) will be collected to be cateogarized to group I or group II. Every group OF FMF will contain 20 FMF women. Both groups will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months. Group I will also perform elliptical aerobic exercise (this exercise will be applied for 40 minutes three times weekly and this exercise will be maintained for 6 months)
Interventions
BEHAVIORALexercise plus diet restriction
Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months. also, this group, Group I, will also perform elliptical aerobic exercise (this exercise will be applied for 40 minutes three times weekly and this exercise will be maintained for 6 months)
BEHAVIORALdiet restriction
Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* familial Mediterrean fever women * obese women * women who have fatty live (non alcoholic type)
Exclusion criteria
* cardiac patients * respiratory disease * renal disease * cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| aspartate transaminase | it will be measured after 6 months | it is a hepatic enzyme |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| body mass index | it will be measured after 6 months | it will be measured after patient emptying his bowel and bladder |
| waist circumference | it will be measured after 6 months | it will be measured at umbilical level |
| high density lipoprotein | it will be measured after 6 months | it will be measured in plasma |
| triglycerides | it will be measured after 6 months | it will be measured in plasma |
| alanine transaminase | it will be measured after 6 months | it is a hepatic enzyme |
| low density lipoprotein | it will be measured after 6 months | it will be measured in plasma |
| c reactive protein | it will be measured after 6 months | it will be measured in plasma |
| erythrocyte sedimentation rate | it will be measured after 6 months | it will be measured in plasma |
| cholesterol | it will be measured after 6 months | it will be measured in plasma |
Countries
Egypt
Contacts
Primary ContactAli MA Ismail, lecturer
Backup ContactAli Ismail, lecturer
Outcome results
None listed